Article
Oncology
Jie-Ru Yang, Ju Wang, Hai-Ming Li, Shuai Gao, Yu-Chen Fan, Kai Wang
Summary: The study found that the IL-6 promoter methylation level is significantly lower in patients with HBV-associated hepatocellular carcinoma, and it is independently associated with the development of liver cancer. The combined use of IL-6 methylation level and AFP can improve the diagnostic accuracy of liver cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shanting Ye, Yong Ni
Summary: The study revealed that upregulated SNHG9 in HCC is associated with shorter disease-free survival, and knocking down SNHG9 can inhibit cell proliferation, block cell cycle progression, and suppress cell migration and invasion by upregulating GSTP1.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Tiantian Liu, Jianni Qi, Hao Wu, Le Wang, Lihui Zhu, Chengyong Qin, Jiao Zhang, Qiang Zhu
Summary: This study identified high expression of PGD in hepatocellular carcinoma (HCC) and found that low PGD expression and hypermethylation predicted better overall survival. Additionally, significant differences in immune cell infiltration were observed between high and low PGD expression groups, with the high expression group showing a more favorable response to immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Peng Huang, Mengxiang Xu, Haijun Han, Xinyi Zhao, Ming D. Li, Zhongli Yang
Summary: DNA methylation plays a crucial role in regulating gene expression in hepatocellular carcinoma (HCC). This study identified a large number of differentially methylated CpG sites in HCC and highlighted the activation of cell cycle-related pathways and repression of metabolic pathways.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Sujatha Peela Bassel F. El-Rayes
Summary: HCC is the most common primary malignancy of the liver, with a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC, including chromatin remodeling, histone alterations, DNA methylation, and ncRNA expression. In-depth understanding of the epigenetics of HCC is critical for developing rational clinical strategies, improving overall survival, and predicting therapeutic outcomes.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Yan Li, Yuanyuan Zheng, Liwei Wu, Jingjing Li, Jie Ji, Qiang Yu, Weiqi Dai, Jiao Feng, Jianye Wu, Chuanyong Guo
Summary: The traditional method of tumor biopsy for hepatocellular carcinoma is limited and there is a need for a novel non-invasive diagnostic technique; circulating tumor DNA technology provides an important method for cancer screening, diagnosis, treatment selection, and prognosis prediction in hepatocellular carcinoma.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Xiao Wang, Mengke Chen, Xiong Liang, Yu Bai, Judeng Zeng, Xiaoyi Xu, Hao Li, Jing Wang, Keyu Fan, Guijun Zhao
Summary: This study reveals that RNF135 is regulated by promoter hypermethylation and its decreased expression is associated with poor prognosis in hepatocellular carcinoma (HCC). Functional analysis demonstrates that RNF135 plays a crucial role in suppressing HCC cell migration and is involved in tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sravan Jeepalyam, Ankur Sheel, Aslam Ejaz, Eric Miller, Ashish Manne
Summary: Using cell-free DNA (cfDNA) to revamp the current biomarker landscape of hepatocellular carcinoma (HCC) could improve overall outcomes. However, the commercially available cfDNA testing is limited and lacks predictive value, making it unreliable for perioperative risk stratification in HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Yating Liu, Lianlian Ouyang, Chao Mao, Yuanbing Chen, Tiansheng Li, Na Liu, Zuli Wang, Weiwei Lai, Yanling Zhou, Ya Cao, Shuang Liu, Yinming Liang, Min Wang, Shouping Liu, Ling Chen, Ying Shi, Desheng Xiao, Yongguang Tao
Summary: Deficiency in PCDHB14 plays a role in the progression of hepatocellular carcinoma (HCC) by inhibiting cell proliferation and inducing ferroptosis. PCDHB14 also serves as a potential prognostic marker for HCC, highlighting its importance in HCC treatment and prognosis.
Article
Biochemistry & Molecular Biology
Diego Camuzi, Luisa Aguirre Buexm, Simone de Queiroz Chaves Lourenco, Rachele Grazziotin, Simone Guaraldi, Priscila Valverde, Davy Rapozo, Jill M. Brooks, Hisham Mehanna, Luis Felipe Ribeiro Pinto, Sheila Coelho Soares-Lima
Summary: Squamous cell carcinoma is the main tumor type in the upper aerodigestive tract (UADT), and the F-box and leucine-rich repeat protein 7 (FBXL7) gene shows potential as a tumor-suppressing gene. This study evaluated the methylation and expression profile of FBXL7 in UADT tumors and found that FBXL7 body is hypomethylated in UADT, regardless of histology. The study also showed a positive correlation between FBXL7 body methylation and gene expression levels in different UADT tumor sites.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Wu Xing, Peng-Cheng Zhou, Hao-Ye Zhang, Li-Min Chen, Yang-Mei Zhou, Xue-Fei Cui, Zhen-Guo Liu
Summary: The study revealed that circ_GLIS2 suppresses the growth and metastasis of HCC by inhibiting cell proliferation, migration, and invasion, while promoting cell apoptosis. This suggests that circ_GLIS2 could potentially serve as a diagnostic marker or therapeutic target for HCC.
LIVER INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Jiaxiu Ma, Jiapei Jin, Huishuang Lu, Jin Zhang, Yalan Li, Xuefei Cai
Summary: This study investigated the role of EXO1 in HCC as a potential diagnostic and prognostic biomarker. The expression of EXO1 was found to be significantly higher in HCC tissues and serums compared to controls. EXO1 expression levels were associated with immune cell infiltration, immune checkpoint genes, and TP53 in HCC tissues. DNA methylation changes in the EXO1 gene were also associated with HCC prognosis. Cox regression analysis showed that EXO1 was an independent risk factor for the overall survival and disease-specific survival of HCC patients. EXO1 expression levels accurately distinguished HCC tissues from normal liver tissues. These findings suggest that EXO1 could be a promising therapeutic target in HCC.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Oncology
Junye Liu, Lulu Xia, Shilei Wang, Xuefei Cai, Xiaoli Wu, Chunhong Zou, Baoju Shan, Miao Luo, Deqiang Wang
Summary: The study revealed the important role of E2F4 in hepatocellular carcinoma (HCC), promoting cancer cell proliferation, migration, and invasion, and potentially serving as a biomarker for HCC.
Review
Oncology
Siyu Fu, Jose D. Debes, Andre Boonstra
Summary: Hepatocellular carcinoma (HCC) is a common primary liver malignancy with poor prognosis. Epigenetic modification, specifically DNA methylation, plays a significant role in HCC development by impacting cell differentiation, proliferation, and function. Methylated DNA markers have shown promise as specific biomarkers for early-stage HCC detection, offering higher sensitivity and specificity compared to current surveillance methods. However, the immediate application of these biomarkers is limited by various factors. This review provides a detailed rationale for using methylation biomarkers in HCC detection and summarizes recent studies on methylated DNA markers, emphasizing the importance of the underlying cause of liver disease in cancer mechanisms.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Srishti Kotiyal, Kimberley Jane Evason
Summary: Mutations in TERT promoter and CTNNB1 gene are common in hepatocellular carcinoma (HCC), and their interaction plays a role in promoting hepatocarcinogenesis.